Skip to main content
Premium Trial:

Request an Annual Quote

Protogene Laboratories,Rosetta Inpharmatics

Premium

Protogene Laboratories of Menlo Park, Calif., announced plans to market, manufacture, and provide custom oligonucleotide DNA microarrays for academic and commercial genomics research scientists. Researchers will be able to specify what they want on a chip and the company will supply them with the finished product within days, said Christopher Wolf, president and CEO of Protogene.

Rosetta Inpharmatics has released version 1.6 of its Rosetta Resolver Expression Data Analysis System. This is the latest release of Rosetta Inpharmatics’ enterprise-wide bioinformatics solution for large-scale gene expression analysis. Enhancements to the system include the addition of several new clustering algorithms and the disclosure of elements of the system’s Application Program Interface. All Rosetta Resolver system customers with an existing support contract will be upgraded to the new version of the product at no additional cost.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.